Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ankelien Duchow

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Neurodegenerative Disease Management|November 10, 2020
Satralizumab in the treatment of neuromyelitis optica spectrum disorderAnkelien Duchow, Judith Bellmann-Strobl
Expert Opinion on Biological Therapy|April 2, 2020
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disordersAnkelien Duchow, Friedemann Paul, Judith Bellmann-Strobl
Expert Opinion on Emerging Drugs|August 1, 2020
Emerging drugs for the treatment of neuromyelitis opticaAnkelien Duchow, Claudia Chien, Friedemann Paul, et al.
Der Nervenarzt|December 14, 2022
[Autoimmune encephalitis-An update]Josephine Heine, Ankelien Duchow, Rebekka Rust, et al.
Frontiers in Neurology|March 29, 2021
Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum DisorderOliver Schmetzer, Elisa Lakin, Ben Roediger, et al.
Scientific Reports|May 14, 2021
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patientsLennard Ostendorf, Philipp Dittert, Robert Biesen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disordersNoah Ayadi, Frederike C Oertel, Susanna Asseyer, et al.
Scientific Reports|October 20, 2022
Structure-function correlates of vision loss in neuromyelitis optica spectrum disordersNorman K Gigengack, Frederike C Oertel, Seyedamirhosein Motamedi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 21, 2021
AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disordersSusanna Asseyer, Hiroki Masuda, Masahiro Mori, et al.
Neurological Research and Practice|May 5, 2026
Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disordersDaria Tkachenko, Ilya Ayzenberg, Louisa M Schöppe, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Neurodegenerative Disease Management|November 10, 2020
Satralizumab in the treatment of neuromyelitis optica spectrum disorderAnkelien Duchow, Judith Bellmann-Strobl
Expert Opinion on Biological Therapy|April 2, 2020
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disordersAnkelien Duchow, Friedemann Paul, Judith Bellmann-Strobl
Expert Opinion on Emerging Drugs|August 1, 2020
Emerging drugs for the treatment of neuromyelitis opticaAnkelien Duchow, Claudia Chien, Friedemann Paul, et al.
Der Nervenarzt|December 14, 2022
[Autoimmune encephalitis-An update]Josephine Heine, Ankelien Duchow, Rebekka Rust, et al.
Frontiers in Neurology|March 29, 2021
Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum DisorderOliver Schmetzer, Elisa Lakin, Ben Roediger, et al.
Scientific Reports|May 14, 2021
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patientsLennard Ostendorf, Philipp Dittert, Robert Biesen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disordersNoah Ayadi, Frederike C Oertel, Susanna Asseyer, et al.
Scientific Reports|October 20, 2022
Structure-function correlates of vision loss in neuromyelitis optica spectrum disordersNorman K Gigengack, Frederike C Oertel, Seyedamirhosein Motamedi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 21, 2021
AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disordersSusanna Asseyer, Hiroki Masuda, Masahiro Mori, et al.
Neurological Research and Practice|May 5, 2026
Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disordersDaria Tkachenko, Ilya Ayzenberg, Louisa M Schöppe, et al.
Pageof 2